Therachon

Author: equq

August undefined, 2024

WebbDevelopment group, serving as its Global Head for Integration Management and Global Head of Alliance Management. His work included the integration of Wyeth, Hospira, Anacor, Medivation, Therachon, Array and most recently Amplyx. He also directly led the separation of. 09 Apr 2024 21:53:51 Webb2 juli 2024 · Pfizer has announced it has completed its acquisition of US-based Therachon, a clinical stage biotechnology company focusing on rare diseases; the acquisition was first initiated in early May 2024.. According to the terms of the transaction, the Swiss pharma giant has bought Therachon for $340m with a potential $470m additional payments …

therachon.com

WebbFresh off a $60 million raise, the Novo Holdings-backed startup Therachon announced plans to buy GLyPharma Therapeutic and make the leap to becoming a multi-asset rare … Webb1 juli 2024 · Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of the privately held clinical-stage biotechnology company Therachon Holding AG. Under the terms of the transaction, Pfizer acquired Therachon for $340 million with an additional $470 million in additional payments contingent on the achievement of key … incorrect syntax near partition

Therachon - Crunchbase Company Profile & Funding

WebbTherAchon is a biotech company specializing in research and development. It is engaged in the development of a recombinant protein therapy for achondroplasia, the most … Webb8 maj 2024 · Therachon is a clinical-stage global biotechnology company focused on the discovery and development of innovative treatment for severe, rare conditions with … WebbHQ / GMP : #712-715, Sagimakgol-ro 137, Jungwon-gu, Seongnam-si, Gyeonggi-do, Korea 13202 R&D Center : #1004-1005, Galmachiro 302, Jungwon-gu, Seongnam-si, Gyeonggi … incorrect syntax near sp_help

Therachon

Webb6 nov. 2024 · Key operating players in global achondroplasia treatment market are Ascendis Pharma A/S, BridgeBio Pharma, Inc., QED Therapeutics, BioMarin Pharmaceutical Inc., Pfizer Inc., Therachon Holding AG, and RIBOMIC Inc. Market Taxonomy: On the basis of drug class, the global achondroplasia treatment market is segmented into: Lipase … Webb8 maj 2024 · May 8, 2024. Pfizer has agreed to acquire Therachon Holdings for up to $810 million, the companies said today, in a deal intended to expand the buyer’s rare disease portfolio with a pipeline to ...

Did you know?

Webb1 juli 2024 · Pfizer Inc. (NYSE: PFE) today announced the successful completion of its acquisition of the privately held clinical-stage biotechnology company Therachon … Webb9 okt. 2024 · BASEL, Switzerland, Oct. 9, 2024 /PRNewswire/ -- Therachon AG ("Therachon"), a clinical-stage biotechnology company focused on treating root causes of rare conditions, today announced the ...

Webb17 maj 2024 · Therachon is a clinical-stage global biopharmaceutical company focused on the discovery, development and commercialization of innovative treatments for severe, rare conditions for which there is ... WebbTherachon is a global biotechnology company focused on developing medicines for rare, genetic diseases that currently have no available treatments. The company’s lead …

Webb26 mars 2024 · We gave two presentations on investigational apraglutide for the treatment of #ShortBowelSyndrome at #ASPEN19!1. Complete Ph 1 trial results 2. Data from head-to-head rat studies comparing apraglutide to other GLP-2 analogs. WebbTherachon AG operates as a biotechnology company. The Company offers novel therapeutics for rare conditions with unmet medical need. Therachon serves customers …

WebbTherachon is a global biotechnology company, focused on developing treatments for rare, genetic diseases that currently have no available treatments. We are committed to the …

Webb17 aug. 2024 · Swiss-based biotech company, Therachon, which focuses on developing rare genetic disease treatments, says it has closed a $60 million round of funding as the company moves closer to a drug trial. The funding will be used to develop the company’s treatment for achondroplasia, the most common form of short limbed dwarfism, and … incorrect syntax near sp_executesqlhttp://theracion.com/ incorrect syntax near sp_helpdbWebb8 jan. 2024 · The founders of Swiss biotech Therachon have launched a new company called VectivBio, also based in Basel, with €31M funding to develop drugs for rare … incorrect syntax near the keyword execWebbPfizer is set to pay $340 million (€304 million) upfront to buy Therachon for Pfizer is set to pay $340 million (€304 million) upfront to buy Therachon for its treatment for a form of … incorrect syntax near sumWebb9 aug. 2024 · Therachon has raised a total of $100M in funding over 3 rounds. Their latest funding was raised on Aug 9, 2024 from a Series B round. Therachon is funded by 9 … incorrect syntax near the keyword andWebb13 mars 2024 · Therachon was focused on the discovery and development of therapeutics for rare pediatric conditions, and was acquired by Pfizer, Inc., in 2024 for $810 million. … incorrect syntax near the keyword identityWebbTherachon General Information. Description. Developer of novel therapeutics intended to facilitate treatment for rare genetic diseases. The company develops pipeline of therapeutics focused on rare gastrointestinal and musculoskeletal disorders and conditions, enabling medical practitioners to treat patients with short bowel syndrome … incorrect syntax near the keyword group